Cas 701299-13-0,tert-butyl 4-((2-methyl-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate

701299-13-0

Post Buying Request

Basic information

Product Name: tert-butyl 4-((2-methyl-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate
Synonyms:
CAS NO:701299-13-0
Molecular Formula:
Molecular Weight: 279.382
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: tert-butyl 4-((2-methyl-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate(CAS DataBase Reference)
NIST Chemistry Reference: tert-butyl 4-((2-methyl-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate(701299-13-0)
EPA Substance Registry System: tert-butyl 4-((2-methyl-1H-imidazol-1-yl)methyl)piperidine-1-carboxylate(701299-13-0)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 701299-13-0(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

701299-13-0 Suppliers

Recommended suppliers

701299-13-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 701299-13-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,1,2,9 and 9 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 701299-13:
(8*7)+(7*0)+(6*1)+(5*2)+(4*9)+(3*9)+(2*1)+(1*3)=140
140 % 10 = 0
So 701299-13-0 is a valid CAS Registry Number.

701299-13-0Upstream product

701299-13-0Downstream Products

701299-13-0Relevant academic research and scientific papers

Discovery of imidazo[1,5-c]imidazol-3-ones: Weakly basic, orally active factor Xa inhibitors

Imaeda, Yasuhiro,Kuroita, Takanobu,Sakamoto, Hiroki,Kawamoto, Tetsuji,Tobisu, Mamoru,Konishi, Noriko,Hiroe, Katsuhiko,Kawamura, Masaki,Tanaka, Toshimasa,Kubo, Keiji

, p. 3422 - 3436 (2008)

The coagulation enzyme factor Xa (FXa) has been recognized as a promising target for the development of new antithrombotic agents. We previously found compound 1 to be an orally bioavailable FXa inhibitor in fasted monkeys; however, 1 showed poor bioavail

PHARMACOLOGICALLY ACTIVE COMPOUNDS

-

Paragraph 00439; 00441, (2014/03/26)

The present invention relates to compounds of formula (II) wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 – also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE

-

Page/Page column 71-72, (2010/02/13)

There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 701299-13-0